Orthopedic Stem Cell Treatment Candidacy: The 5-Factor Assessment Framework That Tells You If You Qualify in 2026

Introduction: Are You a Candidate for Orthopedic Stem Cell Treatment?

Every year, more than 600,000 knee replacements are performed in the United States. Yet research suggests that up to 80% of patients told they need total knee replacement surgery may not actually require it. For people living with joint pain, that statistic raises an obvious and urgent question: is there another way?

Orthopedic stem cell therapy has emerged as one of the most discussed alternatives to surgery. But determining whether someone qualifies for treatment is rarely a simple yes-or-no decision. Candidacy involves a structured, multi-factor evaluation that most patients never see fully explained. Instead, they encounter vague reassurances (“everyone qualifies”) or blunt disqualifiers (“you’re bone-on-bone, sorry”) without any understanding of the reasoning behind them.

This article introduces the 5-Factor Assessment Framework, a structured self-evaluation tool that mirrors how evidence-based clinics like Unicorn Bioscience actually assess patients. Each factor is explained in plain language, including the nuances around X-ray grading, age, medications, and inflammation that most candidacy content ignores entirely.

A note on context: as of 2026, no stem cell products have received FDA approval specifically for orthopedic conditions. That regulatory reality makes thorough candidacy evaluation and transparent communication especially important. At the same time, the evidence base is expanding rapidly, with 224 active clinical trials underway globally, most focused on knee osteoarthritis. The information that follows reflects that growing body of research.

Why a Structured Candidacy Framework Matters

Poorly selected candidates are one of the primary reasons some patients report disappointing outcomes from regenerative treatments. Proper screening protects both patient safety and treatment efficacy. When candidacy is assessed carelessly, patients with unrealistic expectations or unsuitable conditions receive treatment that was unlikely to help them from the start.

The stakes on the surgical side are equally real. Up to 54% of total knee replacement patients report residual symptoms and functional problems after surgery, and between 15% and 30% report outright dissatisfaction with the results. Research also estimates that roughly one-quarter of total knee replacements are performed on inappropriate candidates. These numbers reinforce why exploring regenerative candidacy before committing to an irreversible procedure is worthwhile. Patients uncertain about their surgical recommendation may benefit from a knee replacement second opinion before making a final decision.

Importantly, candidacy is not always binary. Some patients who initially appear to be poor candidates can improve their eligibility through pre-treatment optimization. A comprehensive candidacy assessment typically includes a medical history review, physical examination, imaging analysis, medication review, and baseline functional measurements using validated tools such as the Visual Analog Scale (VAS) and the WOMAC index.

Patient demand is clearly strong. The global orthopedic regenerative surgical products market was valued at roughly $4.59 to $5.17 billion in 2025 and continues to grow. But demand alone does not equal quality. The difference between an evidence-based evaluation and low-quality screening is exactly what the framework below is designed to illuminate.

The 5-Factor Assessment Framework: An Overview

The framework evaluates five interconnected factors:

1. Joint and Tissue Condition Severity
2. Medical History and Absolute Contraindications
3. Medication Status and Washout Requirements
4. Age and Cell Source Compatibility
5. Inflammation Level and Optimization Readiness

These five factors are evaluated together. No single factor alone determines candidacy; it is the interaction between them that a skilled clinician assesses. A patient might have ideal joint severity but a medication conflict that requires planning. Another might be older but an excellent candidate once the right cell source is selected.

This framework is designed for self-evaluation before a consultation, not as a replacement for professional medical assessment. One pattern worth noting: patients who have failed conservative treatments such as physical therapy, cortisone injections, and NSAIDs, but who are not yet at the surgical threshold, are often the strongest candidates.

Factor 1: Joint and Tissue Condition Severity

Osteoarthritis (OA) severity is the single most important candidacy factor in orthopedic stem cell therapy. The standard tool for classifying OA severity on X-ray is the Kellgren-Lawrence (KL) grading system, and understanding where a patient falls on it provides significant insight into candidacy.

In plain language, the KL grades break down as follows:

• Grade 0: No osteoarthritis present.
• Grade I: Minor osteophytes (bone spurs) and doubtful joint space narrowing.
• Grade II: Definite osteophytes with possible joint space narrowing.
• Grade III: Moderate osteophytes, definite narrowing, and some sclerosis (bone hardening).
• Grade IV: Large osteophytes, severe narrowing, and bone-on-bone contact.

How to Read X-Ray Results for Candidacy Purposes

When reviewing a radiology report, patients should look for the KL grade notation along with phrases like “joint space narrowing,” “osteophytes,” or “subchondral sclerosis.” These descriptors map directly to the grading scale above.

The candidacy sweet spot is KL Grade II and III. At these stages, sufficient cartilage remains for stem cells to support repair and regeneration. By contrast, KL Grade IV patients, often described as “bone-on-bone,” typically see diminished results. Stem cells require a viable tissue scaffold to promote healing, and complete cartilage loss removes that substrate.

The data supports this distinction clearly. A 2025 retrospective cohort study of 242 patients found that KL 2/3 patients showed significantly greater gains in KOOS Total, Activities of Daily Living, Sports/Recreation, Quality of Life, and VAS pain scores compared to KL 4 patients following adipose-derived stem cell therapy.

KL Grade IV is not an absolute disqualification in every case. Clinical context, patient goals, and the specific joint involved are all considered. But outcomes data consistently favor earlier-stage disease. Patients with bone-on-bone knees who are not yet ready for surgery may also want to explore whether PRP therapy can help bone-on-bone knees as a complementary or alternative option.

Stem cell therapy is not limited to osteoarthritis. It may also be appropriate for tendon injuries (rotator cuff, Achilles), ligament injuries, meniscus tears, labral injuries, cartilage defects, and osteonecrosis of the femoral head.

Factor 2: Medical History and Absolute Contraindications

Candidacy assessment distinguishes between absolute contraindications, which are automatic disqualifiers, and relative contraindications, which are factors requiring careful evaluation. The transparency that follows is the kind of information most clinics do not publish clearly.

Absolute Contraindications: Who Is Not a Candidate

The following conditions generally rule out stem cell therapy:

• Active cancer or a cancer history within the past 5 years. Stem cells promote cellular growth and tissue repair. In theory, that same growth-promoting environment could support the proliferation of cancer cells, which is why this is treated with caution.
• Active systemic infections. Introducing regenerative cells while the body is fighting an active infection poses safety risks and undermines the healing response.
• Blood-borne diseases such as lymphoma or leukemia not in remission. These conditions affect the very cellular systems involved in regenerative therapy.
• Severe joint degradation with complete cartilage loss in the target joint, as discussed under Factor 1.

A 2025 peer-reviewed safety framework identified oncogenicity and tumorigenicity, immunogenicity, and toxicity as core biosafety risks that inform cell therapy screening. These are the biological reasons behind the disqualifiers above, not arbitrary rules.

Patients with autoimmune conditions, bleeding disorders, or active infections are flagged for special evaluation rather than automatic disqualification. They require additional clinical review before a determination is made.

Relative Contraindications: Factors That Require Careful Evaluation

Relative contraindications include high-dose anticoagulants (such as Coumadin/warfarin), uncontrolled diabetes, a BMI of 40 kg/m² or higher, an intraarticular corticosteroid injection within the previous 3 months, and large “bucket handle” meniscal tears.

BMI deserves special attention because it is a meaningful and addressable candidacy modifier. Obesity (BMI of roughly 35 to 40 or higher) is associated with a 20% to 40% reduction in stem cell therapy success. This is due to both the pro-inflammatory environment created by excess adipose tissue and the increased mechanical loading on the joint.

These criteria are not theoretical. Formal clinical trials operationalize them directly, with exclusion criteria including intraarticular corticosteroid injection within 3 months, BMI of 40 or higher, large meniscal tears, and KL Grade 4 OA in two compartments for patients over 60.

The key point is that relative contraindications are often addressable. A patient who received a corticosteroid injection 10 weeks ago may simply need to wait before proceeding.

Factor 3: Medication Status and Washout Protocols

This is the factor most clinics fail to disclose in detail, yet it directly affects both candidacy and treatment outcomes. Certain medications interfere with stem cell viability, the healing response, or the safety of the harvest and injection procedures.

Medication review should not be viewed as a barrier. It is a manageable preparation step, and most medication-related issues can be resolved with proper planning and physician coordination.

NSAIDs: The Most Common Candidacy Complication

NSAIDs (ibuprofen, naproxen, diclofenac) are the most commonly encountered medication issue in orthopedic stem cell candidacy, simply because most joint pain patients are already taking them.

The mechanism is well documented. A 2024 study confirmed that ibuprofen and diclofenac significantly reduced mesenchymal stem cell viability and altered the expression of apoptosis-related genes, suggesting that concomitant NSAID use can negatively impact therapy efficacy. Separate research in the American Journal of Sports Medicine confirmed that NSAID use after stem cell injection reduces the therapeutic efficacy of mesenchymal stromal cell therapy in posttraumatic osteoarthritis.

The washout window is clear: NSAIDs should generally be discontinued 7 to 42 days before treatment, depending on the specific medication, dosage, and clinical context. Patients should always consult their prescribing physician before stopping any medication. This is a coordination step, not a unilateral patient decision.

Corticosteroids, Blood Thinners, and Other Medications

Several other medication classes are relevant:

• Corticosteroids: These suppress the healing response and the inflammatory signaling that stem cells rely on for integration. The washout window is typically 4 to 6 weeks prior to treatment, and this applies to both systemic forms (such as oral prednisone) and recent intraarticular injections.
• Blood thinners (anticoagulants): These increase bleeding risk at both the cell harvest site and the injection site. Management depends on the specific agent and the patient’s underlying condition, and always requires physician coordination.
• Bisphosphonates (such as Fosamax/alendronate): Used for osteoporosis, these should be paused pre-procedure because they can interfere with bone marrow cell activity.
• Statins: Some evidence suggests they may interfere with mesenchymal stem cell differentiation, so a pause is typically recommended.

Medication washout is not a disqualifier. It is a preparation protocol. Patients on these medications are not automatically excluded; they simply need a timeline and a plan. Unicorn Bioscience’s patient readiness checklist highlights exactly these medication flags, helping patients understand what to address before treatment.

Factor 4: Age and Cell Source Compatibility

Age is one of the most misrepresented factors in competitor content. Some sources claim there is “no age limit” without nuance, while others overstate age as a barrier. The honest, nuanced truth is this: age affects stem cell biology, but it does not necessarily determine treatment outcomes, and the cell source selected can compensate for age-related cell quality decline.

How Age Affects Stem Cell Biology

Older patients do have stem cells with reduced proliferation rates and differentiation potential. This is a biological reality, not a disqualifying judgment.

The specifics matter, however. Bone marrow cells show roughly 36% slower proliferation in older patients, while adipose-derived cells maintain approximately 95% proliferation capacity regardless of patient age. Registry data from approximately 10,000 orthopedic patients found no significant correlation between age and outcome across age groups (50 or younger, 51 to 60, and over 60) for knee treatments, provided appropriate cell sources were used.

Age-outcome relationships are also condition-specific. Research on osteonecrosis of the femoral head suggests patients under 40 may be an ideal age group for that particular condition. For hip conditions more broadly, hip arthritis non-surgical treatment protocols take age into account when designing individualized care plans.

Bone Marrow vs. Adipose-Derived Cells: Why Cell Source Selection Is Age-Relevant

The two primary autologous cell sources used in orthopedic stem cell therapy are bone marrow aspiration concentrate (BMAC) and adipose-derived stem cells harvested from fat tissue.

For older patients, adipose-derived MSCs are generally preferred because they maintain higher proliferation capacity. This makes cell source selection a personalized, age-informed decision rather than a one-size-fits-all protocol. A March 2025 meta-analysis in Stem Cell Research and Therapy found that adipose-derived MSCs showed better efficacy than bone marrow MSCs, and that high-dose treatments (1×10⁸ cells) significantly improved six-month WOMAC scores.

This is precisely why a thorough candidacy assessment addresses not just whether a patient qualifies, but which cell source is right for them. Unicorn Bioscience offers both BMAC and adipose-derived cell therapies, allowing for personalized cell source selection based on patient-specific factors including age. Patients interested in understanding the bone marrow stem cell harvest procedure can review what that process involves before their consultation.

Factor 5: Inflammation Level and Optimization Readiness

Inflammation plays a dual role in candidacy. It is both a signal of active disease and an optimization lever that can be managed to improve outcomes.

A highly inflamed joint microenvironment can accelerate mesenchymal stem cell aging, reduce their stemness, and impair their differentiation capacity, all of which directly reduce treatment efficacy. A 2022 study confirmed that the inflammatory microenvironment is closely associated with accelerated bone marrow stem cell aging, reduced stemness, and impaired differentiation.

Moderate inflammation is expected and acceptable in OA patients. The concern is uncontrolled, severe systemic or local inflammation that overwhelms the regenerative environment.

Pre-Treatment Optimization: Improving Candidacy Profile

Candidacy is not always a fixed state. Borderline candidates can often improve their profile through targeted pre-treatment optimization. Key factors with specific targets include:

• Vitamin D levels of 40 to 60 ng/mL. Deficiency impairs stem cell function.
• BMI under 35. As noted earlier, obesity can reduce success by 20% to 40%.
• Adequate hydration.
• Sufficient protein intake to support tissue repair.

Managing systemic inflammation through lifestyle factors such as weight management, anti-inflammatory nutrition, and reducing NSAID dependence can meaningfully improve the joint microenvironment before treatment. This optimization window conveniently overlaps with the time needed to complete medication washout protocols, turning what might feel like a waiting period into a productive preparation phase.

The takeaway is clear: patients have more agency over their candidacy than they may realize.

Putting It Together: A Pre-Consultation Self-Assessment

The five factors can be synthesized into a practical checklist to use before a consultation. Patients should consider each question honestly:

1. Joint severity: Is the KL grade known? Is it likely in the Grade II to III range?
2. Medical history: Is there any active cancer (or history within 5 years), active infection, or blood-borne disease?
3. Medications: Are NSAIDs, corticosteroids, blood thinners, bisphosphonates, or statins currently being taken?
4. Age and cell source: Is there awareness that cell source options exist and may be relevant based on age?
5. Inflammation and optimization: Have BMI, Vitamin D levels, and medication management been addressed?

Uncertain answers are not disqualifying. They are exactly what a consultation is designed to clarify. Patients who have failed conservative treatments but are not yet at the surgical threshold may be among the strongest candidates, in which case a consultation is strongly warranted.

This self-assessment is a preparation tool, not a diagnostic instrument. Only a qualified clinician can make a formal candidacy determination.

What Happens If a Patient Is Not Currently a Candidate

Not everyone qualifies for stem cell therapy, and honesty about that builds trust. Non-candidacy for stem cells does not mean no regenerative options exist.

Depending on the specific situation, alternatives may include PRP (platelet-rich plasma), BMAC, hyaluronic acid viscosupplementation, exosome therapy, or peptide therapy. Each serves different purposes and may be appropriate where stem cell therapy is not.

Many patients are only temporarily ineligible. Someone who recently received a corticosteroid injection or is currently taking NSAIDs can often become a candidate after a washout period or optimization phase.

There is also an evolving regulatory landscape worth noting. Florida’s SB 1768, effective July 1, 2025, became the first state law allowing licensed physicians to administer FDA-unapproved stem cell therapies for orthopedic conditions, wound care, and pain management, with strict sourcing, consent, and advertising requirements. This expands access for patients at Unicorn Bioscience’s Boca Raton location.

A consultation with a qualified provider remains the definitive way to determine which regenerative pathway, if any, is appropriate.

The Candidacy Assessment Process at Unicorn Bioscience

The formal evaluation process at Unicorn Bioscience mirrors the 5-Factor Framework. It includes a comprehensive medical history review, physical examination, imaging analysis (X-ray for KL grading and MRI for soft tissue evaluation), OA severity assessment, medication review, and baseline functional measurements using validated tools such as VAS and WOMAC scores.

Unicorn Bioscience uses precision-guided injection technology, including ultrasound and X-ray guidance, for all procedures. This is relevant to candidacy because accurate delivery is part of what makes treatment effective for qualified patients. For those who arrive prepared, same-day treatment is available, meaning the consultation and treatment can occur in a single visit.

Both virtual and in-person consultations are offered across 8 locations in Texas, Florida, and New York, making the assessment process accessible regardless of geography.

Unicorn Bioscience also maintains regulatory transparency. The company clearly communicates that as of 2026, stem cell, PRP, and exosome products have not received FDA approval specifically for orthopedic conditions, while noting that substantial clinical evidence supports safety and efficacy when treatments are administered by qualified providers within FDA regulatory frameworks.

Conclusion: Candidacy Is a Starting Point, Not a Final Verdict

Orthopedic stem cell treatment candidacy is a multi-factor, nuanced assessment, not a simple checklist of disqualifiers. The five factors work together: joint severity as measured by KL grading, medical history and contraindications, medication status and washout protocols, age and cell source compatibility, and inflammation level and optimization readiness.

The evidence base behind these criteria is growing rapidly. With 224 active global clinical trials and a $140 million Phase III trial announced in January 2026, candidacy criteria and outcomes data will continue to evolve and sharpen.

Patients who understand these factors arrive at their consultation better prepared. They ask better questions and make more informed decisions about their care. The most important insight separating this framework from basic candidacy content is this: candidacy is not always fixed. It can be optimized. The right clinic will help patients understand not just whether they qualify today, but how to maximize their readiness for the best possible outcome.

Ready to Find Out If You Qualify? Schedule a Candidacy Assessment

For those wondering whether orthopedic stem cell therapy is the right option, the next step is a formal, personalized candidacy evaluation. Unicorn Bioscience offers both virtual and in-person consultations, and qualified candidates may be eligible for same-day treatment, reducing the time between evaluation and care.

With 8 clinic locations across Texas (Austin, Dallas, El Paso, Fort Worth, Houston, and San Antonio), Florida (Boca Raton), and New York (Manhattan), expert assessment is accessible to a broad range of patients. To get started, call (737) 347-0446 or visit unicornbioscience.com to book a consultation online.

The team at Unicorn Bioscience, which includes physicians trained at institutions such as Johns Hopkins, conducts exactly the kind of thorough, personalized assessment described throughout this article. The goal of the consultation is not to sell a treatment. It is to determine whether stem cell therapy is genuinely the right option for a patient’s specific condition, goals, and health profile.